Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a 'Buy' rating from Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the company's lead drug candidate, Lucid-MS. This endorsement underscores the potential of Lucid-MS, described as a potentially first-in-class non-immunomodulatory small molecule, to address neurodegeneration and disability progression in progressive multiple sclerosis (MS), a condition with limited therapeutic options.
The analyst's $8.00 price target reflects a valuation of Quantum BioPharma's development pipeline, with Lucid-MS at the forefront. The drug candidate is being developed to prevent and reverse myelin degradation, the underlying mechanism of MS, as demonstrated in preclinical models. This mechanism offers a novel approach compared to existing immunomodulatory therapies, which primarily target inflammation rather than directly promoting remyelination.
The significance of this rating lies in the urgent need for treatments that can halt or reverse disability progression in progressive MS. Current therapies are often ineffective in the later stages of the disease, leaving patients with few options. Lucid-MS, if successful in clinical trials, could fill this critical gap. The drug's potential to directly address neurodegeneration sets it apart from existing treatments, which focus on immune system modulation.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. The company has also spun out its OTC version of UNBUZZD(TM) to Unbuzzd Wellness Inc., retaining a 19.48% ownership stake (as of June 30, 2026) and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity.
The 'Buy' rating and price target are likely to boost investor confidence in Quantum BioPharma's pipeline and its potential to deliver value. However, investors should be aware that drug development is fraught with uncertainties, including clinical trial outcomes and regulatory approvals. The company's progress in advancing Lucid-MS through clinical development will be closely watched by the investment community.
For more information on Lucid-MS, visit https://nnw.fm/8uqwL. The latest news and updates relating to QNTM are available in the company's newsroom at https://nnw.fm/QNTM.
